NCT05730712 2026-02-06
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
Clinical Trials
4 trialsNCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT02480010 2015-09-18
A Study of Pertuzumab in Participants With Prostate Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT00058539 2015-06-23
Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
Genentech, Inc.
Phase 2 Completed